Introduction
In the preceding paper [1] we have described a new assay to determine the activity of the classical lysosomal enzyme α-N-acetylgalactosaminidase (Naga, EC 3.2.1.49) in serum at pH 4.3, using 2 mM of the chromogenic substrate 2,4-dinitrophenyl-N-acetyl-α-D-galactosiminide (DNP-α-GalNAc). In the present paper, using this substrate, we have tried to verify reports from Yamamoto and co-workers, that serum contains an additional Naga-like activity with a pH optimum at 6. Yamamoto et al. employed a different substrate, para-nitrophenyl-α-GalNAc (pNP-α-GalNAc). They showed that this activity (an exoglycosidase reaction) was often elevated in serum from patients with a wide range of cancers [2] [3] [4] . They named this pH 6 activity 'NaGalase' [4] . However, we were not able to reproduce their result on the basis of their reported experimental details, because they were by no means accurate enough.
In the preceding paper [1] , using 2 mM DNP-α-GalNAc, we found no evidence for Naga-like activities in sera, other than that from the classical lysosomal enzyme at pH 4. In the present study, using a modification of our Naga assay, we have unmasked three additional Naga-like activities. One or two of these could be the activity described by Yamamoto and co-workers [4] .
Materials and methods

General methods and treatment of serum
Most of the used materials and methods was as described in the preceding paper [1] . Serum samples earlier used for tumour-marker analyses, here termed 'TM serum' (TM, tumour marker), came from capped tubes stored for up to 3 days at 4°C. These sera originated from anonymous individuals (females, males, all ages, unless specified otherwise), who had given their consent that after use for the intended analyses, the serum could be used for other purposes, like scientific research. Serum samples were either pooled or assayed individually. Serum referred to as 'routine serum' and 'donor serum', as well as acidification, long-term storage and centrifugation were as described before [1] .
Where indicated, serum was treated with 70% saturated (NH 4 ) 2 SO 4 in 50 mM Na-citrate buffer (citric acid adjusted to pH 5.8 with 5 M NaOH) plus subsequent dialysis of the re-dissolver pellet against the same buffer, exactly as described by Yamamoto and co-workers [4] . In addition, we have also applied this procedure with some minor modifications, i.e. serum was 10-to 50-fold diluted with a solution of 75% sat. (NH 4 ) 2 SO 4 in 50 mM Na-citrate buffer (pH 5.8). After 30 min the suspension was centrifuged (60 min, 3500 × g) and the pellet was completely dissolved in 50 mM Na-citrate buffer (pH 5.8). If indicated, remaining (NH 4 ) 2 SO 4 was removed by one of the following three methods: (a) By dialysis in a Slide-A-Lyser dialysis cassette with 10 MWCO membranes (Pierce) for 2 h in 300 vol 50 mM Na-citrate buffer (pH 5.8) with replacement of the buffer after 30 min and 1 h; (b) By dialysis for 2 h in a normal dialysis bag in 300 vol of buffer with the same intermittent replacements of the buffer as under (a); (c) By a rapid procedure with a size-exclusion column, originally described by Penefsky [5] , using Zeba Desalt Spin Columns (2 mL) from Thermo Scientific (Pierce). These procedures were performed at RT. All dilution factors were taken into account. The dilution due to the acidification of the original serum with 5 M acetic acid (11 μL per mL serum, i.e. 0.989) was the same for all samples. For calculation of the dilution during the (NH 4 ) 2 SO 4 precipitation treatment and subsequent removal of salt, all output volumes were determined by weighing and determination of the specific weight.
A saturated solution of (NH 4 ) 2 SO 4 (MW 132.1) was prepared by adding 69.7 g to 100 mL water at room temperature (RT). The specific weight of this solution was 1.233 g mL − 1 , so its concentration was 3.83 M.
Data treatment
As described in the preceding paper [1] , a slow, spontaneous decomposition of the substrate DNP-α-GalNAc was observed. The rate of this reaction, monitored at 380 nm, was only dependent on temperature and substrate concentration, but not on pH, buffer or salt concentration. At 37°C it followed the equation
, where k = 9.684 × 10
. Invariably, a 2 mM solution showed a DNP production rate of 0.291 nmol min − 1 in an assay volume of 2.5 mL.
Conversion of absorbance changes (dA/dt) to mol min
, using the volume of the assay medium, the pH and Lambert-Beer's law, was carried out as described in the preceding paper [1] . Data handling and line fitting were performed with Microsoft Excel.
Determination of the pH dependence of the enzyme reaction with serum
For activities in the pH range of 3 to 8, a buffer solution of Na 2 HPO 4 in citric acid was used, such that the final concentrations in the assay medium were 70 mM and 50 mM, respectively. The pH of this solution was 4.10. Once filled in a cuvette, the pH was adjusted to the desired pH with either 6 M HCl or 4 M NH 4 OH. The required amounts of acid/ base were pre-determined from a titration of 25 mL of this buffer solution. Just before and after addition of a serum sample, the cuvettes (six at a time) were capped with parafilm and their contents were mixed by hand (final volume 2475 μL). The capped cuvettes were then incubated in a water bath of 35°C for ca. 20 min. After incubation the absorbance at 380 nm (A 380 ) was recorded during ca. 20 min at 37°C. This provided the rate of turbidity change, if any, in each of the cuvettes (enzyme control). Below pH 5 a slight and steady increase at A 380 was often observed, especially with serum that had been stored in the cold room for more than three days. When serum was diluted in buffer at pH values of 5.5 or higher, no such increase was apparent. After ca. 20 min, the parafilm cover was removed and 25 μL substrate (from an ice-cold 200 mM stock solution in DMF) was added, after which the A 380 was recorded for another 30 to 50 min. After cooling to RT, the pH was measured in each individual cuvette.
2.4. The Naga6 assay: the Naga-like activity measured at pH 5.8
Routine Naga6 activity assays were carried out as described above, but in a different buffer. The cuvettes were filled with 1000 μL 125 mM tri-sodium citrate, 70 μL 0.6 M HCl, water and sample (total volume 2475 μL, pH 5.8) prior to incubation and 2 mM substrate addition (25 μL 200 mM in DMF). Note that we use the term Naga6 for the collective Naga-like activities in the pH 5 to 6 region. Because the colour of DNP is dependent on the pH, these cationinduced shifts in the pH reading were neglected in the calculation of the amount of formed DNP in the enzyme assays.
Results
3.1.
Comparison of the pH profile of the DNP production from DNP-α-GalNAc of TM serum with that of routine serum
In the preceding paper ( Fig. 3 in [1] ) a pH profile in 50 mM Nacitrate, 100 mM NaCl (pH range 3 to 6.5) of pooled serum showed one peak of the classical Naga (EC 3.2.1.49) activity around pH 4 (maximal specific activity 1.6 nmol min
). There was no indication for any additional peak in the pH 3.5 to 6.5 region. However, although the activity at pH 6 was low (ca. 0.35 nmol min − 1 mL − 1 ), it was not zero.
In the present study a pH profile between pH 3.5 to 8.0 of pooled TM serum ( Fig. 1 , red curve) was compared with that of pooled, routine serum assayed under identical conditions ( Fig. 1 , black curve). The black curve is similar to that in Fig. 3 from the preceding paper, but contains more data points over a wider pH range. The pH profile of TM serum was very similar to that of the pooled routine serum, but for an apparent higher activity in the pH 5 to 6 region. The activity peak of the classical Naga in the pH 4 region was prominent in both curves. Thus, under normal assay conditions both profiles showed a maximum activity at around pH 4 of 2.2 nmol min
, a minimum at a pH 6.5 and a prominent peak again at pH 8 (up to 1.5 nmol min
).
3.2.
The reaction velocities of Naga6 and the Naga-like activity at pH 8 (Naga8) decreased with increasing serum concentration
Yamamoto and co-workers claimed that the activity with pNP-α-GalNAc at pH 6 was suppressed by an unknown inhibitor in serum [2, 6] . If inhibitors of the Naga6 activity would be present in serum, then, dependent on the nature of inhibition, this might show up in plots of the reaction rate against the serum concentration. Indeed, at pH 6 such a plot, here with TM serum ( Fig. 2A) , clearly deviated from a straight line, while the specific activity strongly decreased with increasing serum concentration. In contrast, at pH 4.3 such plots showed straight lines both with routine and donor serum ( Fig. 2 [1] ), as well as with TM serum (this study; not shown). Like the specific activity at pH 6, the specific activity at pH 8 (Naga8) also decreased with increasing serum concentrations (Fig. 2B ).
Treatment of serum with 70% sat. (NH 4 ) 2 SO 4 and subsequent removal of that salt did not stimulate the Naga6 activity
According to Yamamoto et al. [7, 8] , the inhibitor of the Naga6 activity could be removed by precipitation of the serum protein with 70% saturated (NH 4 ) 2 SO 4 in 50 mM Na-citrate buffer (pH 6) and subsequent dialysis of the re-dissolved pellet against this buffer for ca. 2 h [3] .
We have followed this procedure using pooled TM serum. If an inhibitor can indeed be removed by (NH 4 ) 2 SO 4 precipitation of the protein, and if the inhibitor remains in the supernatant, it is reasonable to assume that sufficient dilution of the serum sample prior to the precipitation step will minimize remnants of the inhibitor in the pellet. It was found that dilution of serum with buffer (at pH 5.8), plus subsequent addition of solid (NH 4 ) 2 SO 4 to 70% saturation gave the same results as dilution of serum with buffer containing 75% sat. (NH 4 ) 2 SO 4 (i.e. a dilution to approximately the same final high concentration of (NH 4 ) 2 SO 4 where all serum proteins precipitate). As an example, the pH profiles of TM serum, before and after (NH 4 ) 2 SO 4 precipitation and subsequent removal of this salt, are shown in Fig. 3 . With the untreated, pooled TM serum (250 μL serum in assay, i.e. 10% serum), a small but notable, broad peak was observed in the pH 5 to 6 region. However, this activity (Naga6) was hardly changed, after the treatment described by Yamamoto. The activity at pH 6.5-7.5 (Naga8) did not increase either. The treatment did not affect the Naga activity at pH 4. Thus, we could not confirm the claim of Yamamoto et al. that (NH 4 ) 2 SO 4 precipitation plus dialysis could remove an inhibitor of the Naga6 activity in serum.
The Naga6 activity was affected by (NH 4 ) 2 SO 4 in the assay
We noticed, that the specific activity at pH 5.8 of the re-dissolved pellet of the (NH 4 ) 2 SO 4 precipitation step was often 2-to 4-fold higher than that of the original serum. However, complete removal of the (NH 4 ) 2 SO 4 (as in Fig. 3 ) reduced this activity again to values equal to, or less than, those of the original serum. This did not depend on the method (see Section 2.1.) to remove the (NH 4 ) 2 SO 4 . The combined results suggested that remnant of (NH 4 ) 2 SO 4 in the solution of the redissolved pellet from the 70% sat. (NH 4 ) 2 SO 4 precipitation step might be responsible for the increase in Naga6 activity.
Indeed, a clear stimulating effect of (NH 4 ) 2 SO 4 on the activity at pH 6 of routine serum was observed (Fig. S2A) . A maximal Naga6 activity (2.8 nmol min − 1 mL
) was obtained with 10% sat. (NH 4 ) 2 SO 4 in the assay medium. Higher concentrations caused inhibition. With 7.5% of the salt, a plot of the Naga6 rate against the serum concentration was still curved (Fig. S2B, trace a) . At low serum concentrations the curve could be extrapolated to the substrate-control rate, measured in the absence of (NH 4 ) 2 SO 4 . This corroborated the finding that the decomposition rate of the substrate is independent of the salt concentration. Trace b in Fig. S2B shows that specific activities of Naga6 up to 4.2 nmol min − 1 mL − 1 were obtained at low serum concentrations.
The stimulating effect of (NH 4 ) 2 SO 4 on the Naga6 activity was also found with donor serum (Fig. S3, trace a) . In that case a nearly 2.5-fold increase was already observed with 4% sat. (NH 4 ) 2 SO 4 . Like in Fig.  S2A , the activity decreased at higher concentrations of the salt. A treatment with 70% sat. (NH 4 ) 2 SO 4 precipitation plus subsequent removal of this salt did not change this behaviour (Fig. S3, trace b) , although a slight decrease of all activities was observed. Again, this experiment did not confirm the reports of Yamamoto et al. [7, 8] that (NH 4 ) 2 SO 4 precipitation plus dialysis results in removal of a Naga6 inhibitor.
Figs. S2A and S3 showed that maximal stimulation of the Naga6 activity by (NH 4 ) 2 SO 4 in routine and donor sera, occurred at different concentrations of the salt. In Fig. S4 these results were combined with the behaviour of three more sera and are plotted in more detail. The figure shows that the effects of (NH 4 ) 2 SO 4 on the Naga6 activity strongly varied with the serum source. However, in all cases a concentration of 1% sat. (NH 4 ) 2 SO 4 induced a significant stimulation (1.3 to 1.8 fold, see red dashed line in Fig. S4B ). At higher concentrations all activities showed a (variable) maximum, above which a slight inhibition was observed. With 300 μL serum (Fig. S4, trace g ) lower activities were found than with 75 μL of the same serum (Fig. S4 , trace f), in line with the findings in Section 3.2.
Optimisation of the assay conditions for the Naga6 activity
In Fig. S4 the effect of (NH 4 ) 2 SO 4 on the Naga6 activity was shown for different serum dilutions (73 to 300 μL serum in a final assay volume of 2.5 mL). As shown in Figs. 2 and S2B, optimal Naga6 activities could only be obtained at much lower serum concentrations. Fig. 4 shows the Naga activity in the pH 3.5 to 6.5 region assayed with only 15 μL TM serum, i.e. 0.6% serum. With this low serum concentration a peak in the pH 4.8 to 5.8 region became very prominent (Fig. 4, trace  a) . Addition of 1% sat. (NH 4 ) 2 SO 4 hardly affected the activity at pH 4.1. However, at this low serum concentration a pronounced stimulating effect was observed in the pH 4.8 to 5.8 region (Fig. 4, trace b) . Note that with the pooled TM serum the maximum Naga6 activity in the presence of 1% sat. (NH 4 ) 2 SO 4 (at pH 5.44) was ca. 1.7-fold higher than the Naga activity at pH 4.1.
Detailed pH profiles of the Naga6 activity in donor and TM sera
In Fig. 5 detailed pH profiles are shown for six donor sera (panel A) and six TM sera (from patients with an elevated PSA-marker value; panel B), using 20 μL serum (0.8% serum) in 2.5 mL buffer with 1% sat. (NH 4 ) 2 SO 4 . Four of the donor sera showed apparent maxima at ca. pH 5.1 and 5.8. These maxima were less prominent in the other two samples. The six TM sera showed apparent maxima at pH 5.2 and 5.6.
When comparing both figures, it can be noted that the variability in the data points with the donor sera was greater than that with the TM sera. In particular, the range in the Naga activities at pH 5.8 (encircled) in the donor sera (1.8 to 3.5 nmol min − 1 mL
) was larger than that in the TM sera (2.1 to 2.7 nmol min − 1 mL − 1 ). The absolute activities of the TM sera were similar to or lower than, but not higher than those observed in the donor sera.
Variability of the Naga activity at pH 4.3 in TM sera
Fig . 5A showed that the Naga6 activity at pH 5.8 in the six donor sera displayed a larger variability than the same activity in six TM sera (Fig. 5B) . To examine whether this also holds for the Naga activity at pH 4.3, a set of 30 TM sera was investigated (Fig. 6A ) and compared to the set of 18 donor sera used in the preceding paper [1] (Fig. 6B) . Whereas the variability in the data points of the 18 donor sera was 13%, it was considerably larger (48%) with the 30 TM sera. Moreover, the average activity of the TM sera (1.42 ± 0.69 nmol min − 1 mL
) was lower than that of donor sera (1.77 ± 0.23 nmol min − 1 mL − 1 ). In addition, the Naga activity in the TM sera seemed to increase from 1.0 to 2.0 nmol min − 1 mL − 1 with decreasing values of the tumour markers.
Substrate inhibition of the Naga6 activity
All the above mentioned assays were performed with 2 mM substrate. To obtain an impression of the K m value of DNP-α-GalNAc for the Naga6 activity, the substrate concentration was varied between 1 and 6 mM, using 25 μL of TM serum. However, the resulting plots (Fig.  S5) were not like those expected for normal Michaelis-Menten kinetics. Instead, they were indicative for substrate inhibition [9] . A similar result was also found with other sera. Thus, the substrate apparently binds to the Naga6 enzyme at a secondary site where it causes inhibition. 
Discussion
Presence in serum of inhibitors of the Naga6 and Naga8 reactions
The decrease of the specific Naga6 activity with increasing serum concentration (Figs. 2 and S2B) is consistent with the notion [2, 6] , that an endogenous inhibitor is affecting its activity in serum. At higher serum concentrations, with more inhibitor present, the activity becomes nearly completely inhibited.
We note, however, that with untreated, pooled TM serum (10% serum in assay), an enhanced activity between pH 5 and 6 was observed in the pH profile which was not observed with routine serum (10% serum in assay, Fig. 1 ). This leaves the possibility open that among the TM-serum samples used to prepare the pooled serum for this experiment, there may have been one or more samples with a strongly enhanced Naga6 activity.
In the assays reported by Yamamoto et al. the medium contained 9% [2] to 15% [3] serum. With cancer patients, before the start of their medical treatment, they found Naga6 activities up to ca. 25 times the values observed in apparently healthy individuals. Such high values have not been observed in the present study. However, in the present study all TM sera were from cancer patients who presumably already received treatment. Therefore, it remains to be firmly established whether the Naga6 activity in serum from cancer patients prior to the start of their treatment is indeed elevated and whether it can serve as a general marker for cancer as proposed by Yamamoto and co-workers [2-4].
Effects of (NH 4 ) 2 SO 4 on the Naga and Naga6 activities
A concentration of 1% sat. (NH 4 ) 2 SO 4 hardly affected the Naga activity at pH 4.3 (Fig. 4) . However, it did stimulate the Naga6 activity in all tested samples (Fig. S4B ), but at higher concentrations the activity decreased again. The concentration required for optimal stimulation of the Naga6 activity was highly dependent on the serum source. The ionic strength of the used buffer (50 mM tri-sodium citrate adjusted with a known amount of 0. Decreasing TM value calculated ionic strength 115 mM) and this could be a possible reason for the enhanced activity. However, addition to the buffer of NaCl, NH 4 We could not detect any increase of the Naga6 activity in serum by 70% sat. (NH 4 ) 2 SO 4 precipitation plus subsequent removal of this salt from the re-dissolved pellet (Figs. 3 and S4) . We note that any remaining (NH 4 ) 2 SO 4 in the re-dissolved pellet after the (NH 4 ) 2 SO 4 precipitation step will enhance this activity. The stimulating effect of this salt is amply shown in the present paper. Therefore, we are inclined to assume that the dialysis procedure of Yamamoto et al. [3] did not remove all (NH 4 ) 2 SO 4 . The remnants (NH 4 ) 2 SO 4 caused a higher Naga6 activity than that of untreated serum.
Possible origin of the Naga6 and Naga8 activities
Figs. 4 and 5 confirm the reports of Yamamoto and co-workers, that serum contains an extra Naga-like activity that can be measured at pH 6 [2] [3] [4] . In fact, our data indicate that there are (presumably) two extra activities in the pH 5 to 6 region with slightly different pH optima. Note that 1% sat. (NH 4 ) 2 SO 4 will shift the pH reading by ca. 0.1 pH unit (Fig.  S1 ), so the pH of the maxima in Fig. 5 should be increased by 0.1 pH unit.
We can only speculate on the possible origin of the Naga6 and Naga8 activities. Den Tandt has described the activities of 14 lysosomal glycohydrolases in blood [10] . One possibility is that the Naga6 and Naga8 activities are side activities of one or more of these enzymes.
Yamamoto and co-workers proposed that the elevated Naga6 activity (Nagalase, an exo-glycosidase activity at pH 6) was an endo-glycosidase excreted by cancer cells [2] [3] [4] . When examining their data, that is a real possibility. They reported that the elevated Naga6 activity drastically decreased one day after removal of the primary tumour or of metastasized lymph nodes [3] . Another group [11] has described similar observations. This is consistent with the proposal that the tumours constantly excrete the enzyme responsible for this activity. The level of the serum activity would then depend on the rate of its formation by the tumours and the rate of its removal from the blood circulation by the patient.
In 2009 it has been reported [12] that recombinant endo-α-N-acetylgalactosaminidase from Streptococcus pneumoniae R6 showed an activity at pH 6.5 with DNP-α-GalNAc (K m 2.4 mM, k cat 1.6 s
, an exoglycosidase activity), which was ca. 0.3% of the activity with DNP-α-GalNAc-3,1-β-Gal (K m 34 μM, k cat 541 s − 1 , the endo-glycosidase activity). Unfortunately, Nagalase has never been purified and/or characterized, so its origin in human serum remains to be investigated.
Units of the Naga6 activity
We have expressed all Naga activities in nmol per min per mL serum (nmol
). However, Yamamoto and co-workers always expressed the Naga6 activity in "nmol min − 1 per mg of serum protein" [4] and serum activities ranged from 0.23 to 0.39 nmol min − 1 mg − 1 in apparently healthy individuals and up to 8 nmol min − 1 mg − 1 in cancer patients [2, 3] . Similar units were also reported by two other groups [11, 13] . Serum contains a large amount of protein (62 to 84 mg mL − 1 ). [14, 15] . The Naga6 activity for serum from healthy individuals reported by Yamamoto would then be two-orders of magnitude greater than the Naga activity. In view of the pH profiles determined in the present paper, this is totally unrealistic. Likewise, based on the assay conditions reported by Yamamoto and coworkers, one can calculate that the substrate pNP-α-GalNAc must have been used up during the 1 h assay. We do not understand these discrepancies. If, by some co-incidence, the units nmol min − 1 mg − 1 [4] should have been nmol min − 1 mL
, then the Naga6 activities in serum from healthy individuals would closely match those in the present paper.
4.6. Importance of the serum Naga6 activity for early detection of cancer Yamamoto and co-workers suggested that the serum Naga6 activity of individual patients might serve as a general diagnostic tumour marker for a broad range of cancers [2] [3] [4] . We note that it cannot be ruled out that the serum Naga6 activity in individuals affected by beginning cancers may increase even before any symptoms of the disease would appear. Thus, we support Yamamoto's suggestion [2] that a regular clinical test for the Naga6 activity may be a valuable tool to help in the detection of upcoming tumours. It would also be interesting to measure whether the Naga activities (at pH 4.3) in potential patients deviate from normal, or do so upon treatment of such patients. Fig. 6 suggests that such anomalies might occur.
Conclusions
We conclude that sera from apparently healthy individuals and from cancer patients contain extra Naga-like activities with pH optima in the pH 5 to 6 region, Naga6, in addition to the classical Naga with an optimum at pH 4. This Naga6 activity is presumably the activity ('Nagalase') that Yamamoto and co-workers have reported on two decades ago [2, 4] . The reason that the Naga6 activity has escaped detection in all earlier studies on the classical lysosomal Naga enzyme in serum, is the fact that high serum concentrations (30 to 50%; see preceding paper [1] ) were used in the enzyme assay. These high concentrations suppress the Naga6 activity. With low serum concentrations in the assay (0.6 to 1%) the Naga6 activity is clearly detectable. Addition of 1% sat. (NH 4 ) 2 SO 4 further enhances this activity. The assay can easily be adapted for use with a plate reader or a spectrophotometer for semi-automatic analysis.
Conflict of interest
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. There are no conflicts of interest.
Transparency document
The Transparency document associated with this article can be found, in online version.
